Impact of biomarker-matched therapies on outcomes in patients with sarcoma enrolled in early-phase clinical trials
Dr. Vivek Subbiah
Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression on standard therapies, patients with sarcoma may be referred for enrollment in early-phase trial. The SAMBA 101 retrospective analysis found that among patients with advanced sarcoma after progression on standard therapies, enrollment in early phase biomarker-matched trials of MD Anderson Cancer Center (Houston, TX) was associated with higher response rate and longer PFS and OS.
